AQR Capital Management
ITCI

AQR Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AQR Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-266,327
Closed -$35.1M – 3427
2025
Q1 		$35.1M Sell
266,327
-270,454
-50% -$33.7M 0.04% 562
2024
Q4 		$44.8M Buy
536,781
+74,949
+16% +$6.16M 0.06% 417
2024
Q3 		$33.8M Buy
461,832
+356,401
+338% +$26.8M 0.05% 476
2024
Q2 		$7.22M Buy
105,431
+26,486
+34% +$1.84M 0.01% 865
2024
Q1 		$5.46M Buy
78,945
+40,232
+104% +$2.77M 0.01% 940
2023
Q4 		$2.77M Buy
38,713
+8,774
+29% +$505K 0.01% 1199
2023
Q3 		$1.56M Buy
29,939
+13,793
+85% +$804K ﹤0.01% 1431
2023
Q2 		$1.02M Buy
16,146
+2,697
+20% +$168K ﹤0.01% 1544
2023
Q1 		$728K Sell
13,449
-5,542
-29% -$268K ﹤0.01% 1647
2022
Q4 		$1.01M Sell
18,991
-1,354
-7% -$67.9K ﹤0.01% 1563
2022
Q3 		$947K Sell
20,345
-2,702
-12% -$141K ﹤0.01% 1542
2022
Q2 		$1.32M Buy
23,047
+13,222
+135% +$750K ﹤0.01% 1302
2022
Q1 		$601K Buy
9,825
+1,303
+15% +$67.7K ﹤0.01% 1748
2021
Q4 		$446K Hold
8,522
– – ﹤0.01% 1860
2021
Q3 		$318K Hold
8,522
– – ﹤0.01% 2021
2021
Q2 		$348K Sell
8,522
-9,872
-54% -$365K ﹤0.01% 2006
2021
Q1 		$624K Sell
18,394
-14,441
-44% -$501K ﹤0.01% 1753
2020
Q4 		$1.04M Sell
32,835
-18,813
-36% -$494K ﹤0.01% 1486
2020
Q3 		$1.32M Sell
51,648
-10,282
-17% -$235K ﹤0.01% 1283
2020
Q2 		$1.59M Buy
61,930
+616
+1% +$12.5K ﹤0.01% 1272
2020
Q1 		$942K Buy
+61,314
New +$1.33M ﹤0.01% 1361
2019
Q1 		– Sell
-19,837
Closed -$226K – 2233
2018
Q4 		$226K Sell
19,837
-5,275
-21% -$85.2K ﹤0.01% 2045
2018
Q3 		$545K Buy
25,112
+146
+0.6% +$3.05K ﹤0.01% 1927
2018
Q2 		$441K Buy
+24,966
New +$507K ﹤0.01% 2020
2016
Q4 		– Sell
-18,864
Closed -$287K – 2290
2016
Q3 		$287K Buy
18,864
+1,702
+10% +$68.8K ﹤0.01% 2092
2016
Q2 		$666K Sell
17,162
-3,652
-18% -$131K ﹤0.01% 1761
2016
Q1 		$579K Sell
20,814
-16,042
-44% -$535K ﹤0.01% 1782
2015
Q4 		$1.98M Sell
36,856
-5,572
-13% -$281K ﹤0.01% 1244
2015
Q3 		$1.7M Buy
42,428
+10,327
+32% +$337K ﹤0.01% 1204
2015
Q2 		$1.03M Buy
32,101
+21,201
+195% +$538K ﹤0.01% 1482
2015
Q1 		$260K Buy
+10,900
New +$244K ﹤0.01% 1934

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AQR Capital Management's ITCI Position: Q2 2025 in Review

AQR Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 266,327 shares — an estimated $35.1M sold.

AQR Capital Management first reported a position in ITCI in Q1 2015 and held it in 31 quarters. The position peaked at $44.8M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • AQR Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • AQR Capital Management sold 266,327 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $35.1M.
  • AQR Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 31 quarters.
  • AQR Capital Management's Intra-Cellular Therapies Inc. position peaked at $44.8M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on AQR Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.